Could we expect to improve survival in small cell lung cancer?

  title={Could we expect to improve survival in small cell lung cancer?},
  author={Ghassan El Maalouf and J M Rodier and Sandrine J. Faivre and Eric Raymond},
  journal={Lung cancer},
  volume={57 Suppl 2},
Despite the very good response rate of small cell lung cancer (SCLC) to many anti-cancer agents, survival remains disappointing, particularly in extensive-stage (ES) disease. Many potentially beneficial regimens have achieved a median survival of less than 12 months in clinical trials, and so the standard regimen has remained cisplatin plus etoposide. Trials have shown that 3- and 4-drug regimens are no better than 2-drug regimens; alternating agents, dose-dense and high-dose regimens do not… CONTINUE READING
10 Citations
0 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…